Skip to main content
. 2015 Jul 27;112(32):9990–9995. doi: 10.1073/pnas.1510837112

Fig. 3.

Fig. 3.

Activation of the BMP-BMPR-Smad1/5-70S6K pathway conferred resistance to EGFR-TKIs in lung SqCC cells and patients with EGFR mutations. (A–C) The indicated cell lines were treated with erlotinib (1 μM) for 24 h. Cell extracts were immunoblotted to detect the indicated proteins. (D) Cell viability analysis showed that cotreatment with either BMP2 (10 ng/mL) or BMP4 (10 ng/mL) with erlotinib conferring stronger resistance to erlotinib in Beas/2b-19del cell line. Viability at 72 h was calculated as the ratio of drug-treated cells to viable DMSO-treated cells. (E and F) Formalin-fixed, paraffin-embedded sections (4 μm) were stained for BMPR-II and phos-70S6K. (E) Numbers of cases with positive proteins grouped by PFS after EGFR-TKI in lung SqCC patients (n = 10). (F) Numbers of cases with positive proteins grouped by PFS after EGFR-TKI in lung adenocarcinoma patients (n = 11).